Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients With Immune Thrombocytopenia (ITP)

Inclusion Criteria: * Adult patients with ITP * platelet counts \< 25 x10\*9/L or \< 50 x10\*9/L with bleeding symptoms * meets criteria for treatment with TPO-ra * Females must use contraceptives when applicable for at least three months before inclusion Exclusion Criteria: * Pregnancy or nursing * Former thromboembolic events excluding one incidence of deep venous thrombosis as complication to surgery or pregnancy or one incidence of cerebral embolism as complication to atrial fibrillation * Liver insufficiency (for eltrombopag only) * TPO-ra contraindications (e.g. allergy) * TPO-ra treatments less than 6 months prior to inclusion